FIXX News and Press, Homology Medicines Inc. From 08/04/21

BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences: BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m. E...

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...

Political change along with updated White House priorities have certainly created a need to review investment portfolios. As the national focus shifts from one area of fulfilling citizens' wants and needs to another, some industries are getting more attention while others are put on “hi...

- Data From New GTx-mAb Platform Demonstrated Proof of Principle for AAVHSCs to Deliver One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model - - Additional Data for HMI-203 Gene Therapy in Hunter Syndrome and HMI-103 Gene Editing in PKU Support...

Homology Medicines (FIXX): Q1 GAAP EPS of -$0.02 beats by $0.62.Revenue of $29.31M (+4867.8% Y/Y) beats by $28.72M.Press Release For further details see: Homology Medicines EPS beats by $0.62, beats on revenue

- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End - - Announced New GTx-mAb Platform With Proof of Concept Data to Be Presented at Upcoming ASGCT Annual Meeting - - Presented Data Demonstrating Nuclease-Free Gene Editing of Retinal Cells ...

- Data Showed AAVHSCs Edited Human Retinal Cell Types Across Two Targets - - Demonstrated 11 AAVHSC Capsids Crossed Blood-Retinal and Blood-Brain Barriers in In Vivo Studies of Non-Human Primates With Single I.V. Dose - BEDFORD, Mass., May 03, 2021 (GLOBE NEW...

- Proof of Concept Data for New GTx-mAb Platform to Be Featured at ASGCT Along With Presentations From Multiple Programs - - Company to Host Webcast on May 13 at 8:15 a.m. ET - BEDFORD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clin...

Shares of Homology Medicines Inc. (NASDAQ:FIXX) traded today at $6.35, breaking its 52-week low. This new low was reached on approximately average trading volume as 857,000 shares traded hands, while the average 30-day volume is approximately 820,000 shares. Homology Medicines Inc. (NASD...

Homology Medicines Inc. (NASDAQ:FIXX) traded at a new 52-week low today of $6.50. Approximately 857,000 shares have changed hands today, as compared to an average 30-day volume of 810,000 shares. Potential upside of 2.5% exists for Homology Medicines Inc., based on a current level of $6....